TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3063047

Group type: EXPERIMENTAL
Intervention: Alinidine (0.6 mg.kg‐1 i.v.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metoprolol (0.035 mg.kg‐1 i.v.)
Number of subjects: 24
Study: 29898585

Group type: EXPERIMENTAL
Intervention: Treadmill training, stretching, respiratory, and proprioceptive exercises (TreSPE study)
Number of subjects: 53

Group type: COMPARATOR
Intervention: CMT Neuropathy Score, 6MWT, 10MWT, Berg Balance Scale (BBS), Short Physical Performance Battery (SPPB), SF36, Walk12
Number of subjects: 53
Study: 29049194

Group type: EXPERIMENTAL
Intervention: Action observation therapy (8 weeks, 6 times per week, 20 minutes per session)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional rehabilitation treatments
Number of subjects: 53
Study: 27115508

Group type: EXPERIMENTAL
Intervention: Real tDCS (1.5 mA, cathodal over bilateral FPT for 20 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control tDCS stimulation (turning off the stimulation after 30 s)
Number of subjects: 20
Study: 25099476

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 91
Study: 22161999

Group type: EXPERIMENTAL
Intervention: General approach to scan GWAS SNP data for gene-level and gene-set analyses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of methods to two different GWAS.
Number of subjects: 0
Study: 19393840

Group type: EXPERIMENTAL
Intervention: Immediate-release quetiapine fumarate (IR)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (XR)
Number of subjects: 63
Study: 17905960

Group type: EXPERIMENTAL
Intervention: Percutaneous Compression Plate (PCCP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Compression Hip Screw (CHS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PCCP
Number of subjects: 104
Study: 15309258

Group type: EXPERIMENTAL
Intervention: Dexpanthenol nasal spray (5%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dexpanthenol nasal ointment (5%)
Number of subjects: 20
Study: 11746320

Group type: EXPERIMENTAL
Intervention: Mean function regression model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random effects models
Number of subjects: 0
Study: 10574380

Group type: EXPERIMENTAL
Intervention: Bimodal (audio-visual) speech stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unimodal (auditory and visual) components
Number of subjects: 0
Study: 7883933

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50:50 mixture with oxygen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular sedation (meperidine and promethazine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular sedation
Number of subjects: 30
Study: 2204333

Group type: EXPERIMENTAL
Intervention: Continuous interpleural infusion of bupivacaine (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous infusion of papaveretum (n = 8)
Number of subjects: 16
Study: 723506

Group type: EXPERIMENTAL
Intervention: Circuit Weight Training (CWT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Running (RN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 31613424

Group type: EXPERIMENTAL
Intervention: Acupressure on SP6 point
Number of subjects: 60
Study: 31416506

Group type: EXPERIMENTAL
Intervention: Clopidogrel combined with aspirin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin and aspirin
Number of subjects: 77
Study: 29020372

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 27
Study: 25050456

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 65 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23772186

Group type: EXPERIMENTAL
Intervention: Peer buddy system (PBS) to promote CPAP adherence
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 52
Study: 21718908

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome present (+MetS)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein cholesterol
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Elevated glucose
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (unadjusted)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (adjusted)
Number of subjects: 2248

Group type: COMPARATOR
Intervention: Early percutaneous coronary intervention
Number of subjects: 2248
Study: 19549287

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous alanyl‐glutamine dipeptide (20 g for 5 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (same chemotherapy regimens as screening cycle)
Number of subjects: 44
Study: 17560446

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (3-h intervals)
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (3-h intervals)
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (12-h intervals)
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (12-h intervals)
Number of subjects: 2066
Study: 15140778

Group type: EXPERIMENTAL
Intervention: Standardised tools (ST)
Number of subjects: 2957

Group type: EXPERIMENTAL
Intervention: Exercises (EX)
Number of subjects: 2957

Group type: EXPERIMENTAL
Intervention: Both tools and exercises (ST+EX)
Number of subjects: 2957

Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 2957
Study: 11426001

Group type: EXPERIMENTAL
Intervention: 2 mmol/L gadoteridol
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 4 mmol/L gadoteridol
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 156
Study: 10025043

Group type: EXPERIMENTAL
Intervention: Specific acupuncture therapy (verum)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-specific acupuncture therapy (placebo)
Number of subjects: 24
Study: 8008413

Group type: EXPERIMENTAL
Intervention: Phentolamine (30 mg) administered intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1987713

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day, 4 times per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 735882

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10
Study: 31060604

Group type: EXPERIMENTAL
Intervention: INCREM (Functional Remediation + Computerized Cognitive Training)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus online games
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 81
Study: 27884418

Group type: EXPERIMENTAL
Intervention: 400 cGy dose of radiation
Number of subjects: 147

Group type: COMPARATOR
Intervention: 700 cGy dose of radiation
Number of subjects: 147
Study: 25881841

Group type: EXPERIMENTAL
Intervention: Total Disc Arthroplasty (TDA)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 4
Study: 23204536

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 2
Study: 16759297

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 717

Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 717

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 717
Study: 14769785

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sulfafurazole (sulphisoxazole) 50 mg/kg body weight, given once a day for six months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 10935668

Group type: EXPERIMENTAL
Intervention: Systematic nurse and pharmacist led education including an interactive Kodak Photo‐CD Portfolio technique
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Systematic education
Number of subjects: 130
Study: 8873199

Group type: EXPERIMENTAL
Intervention: High involvement (student loan) with high intonation and intensity of voice
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Low involvement (ATM cards) with low intonation and intensity of voice
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: High involvement (student loan) with low intonation and intensity of voice
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Low involvement (ATM cards) with high intonation and intensity of voice
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Characteristics of voice (intensity and intonation)
Number of subjects: 279
Study: 1738544

Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium and clavulanate potassium (Timentin) administered intravenously at the time of surgery and for 12 hours postoperatively, followed by oral amoxicillin and clavulanate potassium (Augmentin) therapy for an additional seven days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo administered intravenously at the time of surgery and for 12 hours postoperatively, followed by placebo for an additional seven days
Number of subjects: 101
Study: 6391067

Group type: EXPERIMENTAL
Intervention: Tizanidine (up to 12 mg a day for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31339676

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 613

Group type: COMPARATOR
Intervention: Low-dose efavirenz (EFV400)
Number of subjects: 613
Study: 26919705

Group type: EXPERIMENTAL
Intervention: Augmentation with chin bone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Augmentation with chin bone plus a membrane
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Augmentation with a bone substitute plus a membrane
Number of subjects: 93
Study: 25444377

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1498
Study: 23534416

Group type: COMPARATOR
Intervention: Established Market Economies
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Eastern Europe
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Asia
Number of subjects: 11140
Study: 21854383

Group type: EXPERIMENTAL
Intervention: Forensic statement analysis (FSA) methods
Number of subjects: 35

Group type: COMPARATOR
Intervention: Deceptive eyewitness accounts
Number of subjects: 35
Study: 19423519

Group type: EXPERIMENTAL
Intervention: Moisturizers with SPF 15
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moisturizers with no stated SPF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sunscreen with SPF 30 or 45
Number of subjects: 30
Study: 16236787

Group type: EXPERIMENTAL
Intervention: Repeated trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrepeated trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus presentation durations longer than required for recognition (2 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus presentation durations close to the minimum time required for recognition (85-101 ms)
Number of subjects: 0
Study: 12942722

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) monotherapy - 300 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Maximal androgenic block (MAB) - CA + surgical castration - 200 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Maximal androgenic block (MAB) - CA + drug castration - 200 mg/day
Number of subjects: 70
Study: 10575270

Group type: EXPERIMENTAL
Intervention: Low-dose BCG regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow-rate BCG regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG immunotherapy (standard regimen)
Number of subjects: 0
Study: 9161270

Group type: EXPERIMENTAL
Intervention: Samarium compound filter with E-speed film
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional aluminum filter with E-speed film
Number of subjects: 39
Study: 1533209

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study: 3880867

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (10 g daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 100
Study: 31243803

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IIM)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 1512
Study: 30033196

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied every 3 days for children with up to three incontinence episodes per day, and daily for those with more frequent episodes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study: 26629967

Group type: EXPERIMENTAL
Intervention: 3-hydroxyphthalic anhydride-modified bovine beta-lactoglobulin (JB01)
Number of subjects: 38
Study: 25260813

Group type: EXPERIMENTAL
Intervention: Successful radial access (RA)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Successful femoral access (FA)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Crossover (failed RA with need for bailout FA)
Number of subjects: 241
Study: 22803423

Group type: EXPERIMENTAL
Intervention: PPI + DG group (Rabeprazole 20 mg once daily; DG 6 g thrice daily)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group A (Rabeprazole Capsule 20 mg once daily)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group B (Rabeprazole 20 mg once daily; Domperidone 10 mg thrice daily)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study: 20139291

Group type: EXPERIMENTAL
Intervention: Extended model of care (usual care + self-management group intervention)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study: 16831828

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 and TNFα inhibitors
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patient years
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Annual standard incidence ratios (SEER)
Number of subjects: 70
Study: 16047527

Group type: EXPERIMENTAL
Intervention: Telemarketing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Academic detailing (personal visits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supported GPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control GPs (written guidance only)
Number of subjects: 0
Study: 14612286

Group type: EXPERIMENTAL
Intervention: Urinary trypsinogen activation peptide (TAP) at admission
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Urinary TAP concentrations on days 2 to 3
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: APACHE II scores at 48 h after admission
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Admission urinary TAP >=35 nmol/L for severe pancreatitis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: APACHE II scores (>=9) at 48 h after admission
Number of subjects: 41
Study: 10395878

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP-Hib combination vaccines
Number of subjects: 0
Study: 7726672

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 58
Study: 1903732

Group type: EXPERIMENTAL
Intervention: GnRH-a initiated during the luteal phase (Group B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: GnRH-a initiated during the follicular phase (Group C)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (Group A) - pure FSH human menopausal gonadotropin (hMG) protocol
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both GnRH-a protocols (Group B and C)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: GnRH-a during follicular phase (Group C)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: GnRH-a during luteal phase (Group B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All three protocols (A, B, C)
Number of subjects: 192
Study: 6787107

Group type: EXPERIMENTAL
Intervention: Alrestatin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31600487

Group type: EXPERIMENTAL
Intervention: Infliximab monotherapy
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Adalimumab combination therapy
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy alone
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy in combination with an immunomodulator
Number of subjects: 1240
Study: 30209855

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT) for 8 weeks, using threshold loading with a target workload of maximal inspiratory pressure (MIP) of at least 70%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-intensity inspiratory muscle training at 10% of initial MIP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (H-IMT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-intensity inspiratory muscle training
Number of subjects: 45
Study: 28504542

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 134
Study: 25990414

Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinylestradiol 20 μg/desogestrel 150 μg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (non-users of COCs)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Comparison of BMC percentage variation
Number of subjects: 67
Study: 24078799

Group type: EXPERIMENTAL
Intervention: ACES-based curriculum
Number of subjects: 335

Group type: COMPARATOR
Intervention: Standard sex education curriculum (Control)
Number of subjects: 335
Study: 21416421

Group type: EXPERIMENTAL
Intervention: Entertainment-education (E-E) program
Number of subjects: 437

Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 437

Group type: COMPARATOR
Intervention: Entertainment program
Number of subjects: 437
Study: 19661809

Group type: EXPERIMENTAL
Intervention: Moderate risk case (n = 25)
Number of subjects: 86

Group type: COMPARATOR
Intervention: High-risk paternal case (n = 33)
Number of subjects: 86

Group type: COMPARATOR
Intervention: High-risk maternal case (n = 28)
Number of subjects: 86
Study: 17907591

Group type: EXPERIMENTAL
Intervention: HFA-based budesonide inhaler therapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: CFC-based budesonide inhaler therapy
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: High-dosage (1,600 microg/day) HFA and CFC inhalers
Number of subjects: 321
Study: 15534056

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG imaging
Number of subjects: 59

Group type: COMPARATOR
Intervention: Labeled leukocyte/marrow imaging
Number of subjects: 59
Study: 11526761

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 34

Group type: COMPARATOR
Intervention: Leuprolein acetate
Number of subjects: 34
Study: 9146848

Group type: EXPERIMENTAL
Intervention: Triazolam + Diltiazem (0.25 mg triazolam after 3-day treatment of 180 mg diltiazem)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7966506

Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI)
Number of subjects: 0
Study: 2885203

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg with alcohol 32 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg with alcohol 32 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg and 120 mg with alcohol 32 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg with alcohol 32 ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30458805

Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training in same cycle (CTSC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training in different cycles (CTDC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training (CTSC and CTDC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) and Combined inspiratory and expiratory muscle training in different cycles (CTDC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: IMT, CTSC, and CTDC
Number of subjects: 92
Study: 26494415

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) using interstitial multicatheter brachytherapy
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Whole-breast irradiation with tumour-bed boost
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1184
Study: 23916045

Group type: COMPARATOR
Intervention: Colesevelam (alone or in combination with statins) in pediatric patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colesevelam (added to a maximally tolerated regimen of a statin plus ezetimibe) in adult patients
Number of subjects: 0
Study: 20645531

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18374052

Group type: EXPERIMENTAL
Intervention: Self-study with video
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Self-study with interactive video
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Self-study with interactive video plus expert instruction
Number of subjects: 3